anti-GD2 antibody-drug conjugate M3554

{
  "id": "MLC-T-ONC-010685",
  "term": "anti-GD2 antibody-drug conjugate M3554",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of the humanized monoclonal antibody dinutuximab (ch14.18) directed against the tumor-associated antigen (TAA) disialoganglioside (GD2; GD-2) conjugated, via a cleavable beta-glucuronide linker, to the camptothecin analog and topoisomerase 1 inhibitor exatecan, with potential antineoplastic activity. Upon administration of anti-GD2 ADC M3554, dinutuximab targets and binds to GD2 expressed on tumor cells. Upon binding, internalization and linker cleavage, exatecan is released. Exatecan inhibits DNA topoisomerase 1 activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of GD2-expressing tumor cells. GD2 is overexpressed in certain tumor types including neuroblastoma, osteosarcoma, glioma and soft tissue sarcoma.",
  "synonyms": [
    "anti-GD2 ADC M3554",
    "anti-GD2/exatecan ADC M3554"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-gd2-antibody-drug-conjugate-m3554/"
}